WHAT IS CLAIMED IS:

1. ~~An~~A placental extracellular matrix (ECM) composition comprising ~~about~~ 35-55% collagen by dry weight and ~~about~~ 10-30% elastin by dry weight.

2. The composition of claim 1, wherein said composition comprises less than 0.1% fibronectin.

3. The composition of claim 1 or 2, wherein said composition comprises an undetectable amount of laminin.

4. The composition of any one of claims 1-3, wherein said composition comprises an undetectable amount of glycosaminoglycans.

5. The composition of claim 1, wherein said composition comprises less than 0.1% fibronectin, an undetectable amount of laminin, and an undetectable amount of glycosaminoglycans.

6. ~~An~~A placental ECM composition comprising ~~about~~ 40-70% collagen by dry weight and ~~about~~ 15-25% elastin by dry weight.

7. The composition of claim 6, wherein said composition comprises less than ~~about~~ 0.1% fibronectin by dry weight.

8. The composition of claim 6 or 7, wherein said composition comprises less than ~~about~~ 0.1% laminin by dry weight.

9. The composition of any one of claims 6-8, wherein said composition comprises less than ~~about~~ 0.1% glycosaminoglycans by dry weight.

10. The composition of any one of claims 6-9, wherein said composition comprises an undetectable amount of cytokines, growth factors or deoxycholic acid.

11. The composition of claim 6, wherein said composition comprises less than ~~about~~ 0.1% fibronectin by dry weight, less than about 0.1% laminin by dry weight, less than ~~about~~ 0.1% glycosaminoglycans by dry weight, and an undetectable amount of cytokines, growth factors or deoxycholic acid.

~~12. The composition of claim 11, wherein said composition comprises less than about 0.1% fibronectin, less than about 0.1% laminin, less than about 0.1% glycosaminoglycans, and an undetectable amount of cytokines, growth factors and deoxycholic acid.~~

~~13. The composition of any one of claims 1-12, wherein said ECM is placental ECM.~~

~~14.~~12. The composition of claim ~~13~~11, wherein said placental ECM is human placental ECM.

~~15.~~13. The composition of any one of claims 1-~~13~~12, wherein said composition is formulated as a sheet.

~~16.~~14. The composition of claim ~~15~~13, wherein said sheet is ~~about~~ 1.5 to 2.5 mm thick.

~~17.~~15. The composition of any one of claims 1-~~16~~12, wherein said composition is formulated as a particulate.

~~18.~~16. The composition of any one of claims 1-~~16~~12, wherein said composition is formulated as a flowable matrix.

~~19.~~17. ~~An ECM composition comprising about 35-55% collagen and about 10-30% elastin, wherein said ECM composition is prepared according to the following method~~ A method of preparing an ECM composition according to any one of claims 1-5, comprising: (i) removing the amnion, chorion, and umbilical cord from a placenta; (ii) placing the remaining placental tissue in a solution comprising 1 M NaCl; (iii) homogenizing the placental tissue; (iv) contacting the placental tissue with a solution comprising 2% sodium deoxycholate; (v) washing the placental tissue with water; (vi) contacting the placental tissue with a solution comprising 1 M sodium hydroxide; (vii) bringing the solution comprising the placental tissue to a neutral pH; and (viii) collecting the placental tissue.

~~20. The composition of claim 19, wherein said composition comprises less than 0.1% fibronectin.~~

~~21. The composition of claim 19 or 20, wherein said composition comprises an undetectable amount of laminin.~~

~~22. The composition of any one of claims 19-21, wherein said composition comprises an undetectable amount of glycosaminoglycans.~~

~~23. The composition of claim 22, wherein said composition comprises less than 0.1% fibronectin, an undetectable amount of laminin, and an undetectable amount of glycosaminoglycans.~~

~~24.~~18. ~~An ECM composition comprising about 40-70% collagen and about 15-25% elastin, wherein said ECM composition is prepared according to the following method~~A method of preparing an ECM composition according to any one of claims 6-11, comprising: (i) obtaining the chorion from a placenta; (ii) scraping and cleaning the chorion; (iii) placing the

chorion tissue in solution comprising 0.5 M NaCl; (iv) contacting the chorion with a solution comprising 2% deoxycholic acid or sodium deoxycholate; (v) rinsing the chorion with water; and (vi) grinding and freeze drying.

~~25. The composition of claim 24, wherein said composition comprises less than about 0.1% fibronectin.~~

~~26. The composition of claim 24 or 25, wherein said composition comprises less than about 0.1% laminin.~~

~~27. The composition of any one of claims 24-26, wherein said composition comprises less than about 0.1% glycosaminoglycans.~~

~~28. The composition of any one of claims 24-27, wherein said composition comprises an undetectable amount of cytokines, growth factors or deoxycholic acid.~~

~~29. The composition of claim 24, wherein said composition comprises less than about 0.1% fibronectin, less than about 0.1% laminin, less than about 0.1% glycosaminoglycans, and an undetectable amount of cytokines, growth factors or deoxycholic acid.~~

~~30. The composition of claim 29, wherein said composition comprises less than about 0.1% fibronectin, less than about 0.1% laminin, less than about 0.1% glycosaminoglycans, and an undetectable amount of cytokines, growth factors and deoxycholic acid.~~

~~31.~~19. ~~An ECM composition comprising about 40-70% collagen and about 15-25% elastin, wherein said ECM composition is prepared according to the following method~~A method of preparing an ECM composition according to any one of claims 6-11, comprising: (i) obtaining the chorion from a placenta; (ii) scraping and cleaning the chorion; (iii) placing the chorion in a solution comprising 1.0 M NaCl; (iv) contacting the chorion with a first detergent solution comprising ~~about~~ 0.05-0.1% deoxycholic acid or sodium deoxycholate and ~~about~~ 3mM-5mM EDTA, following by water rinsing; (iv) contacting the chorion with a second detergent solution comprising ~~about~~ 0.05-0.1% deoxycholic acid or sodium deoxycholate, followed by water rinsing; (v) and freeze drying.

~~32. The composition of claim 31, wherein said composition comprises less than about 0.1% fibronectin.~~

~~33. The composition of claim 31 or 32, wherein said composition comprises less than about 0.1% laminin.~~

~~34. The composition of any one of claims 31-33, wherein said composition comprises less than about 0.1% glycosaminoglycans.~~

~~35. The composition of any one of claims 31-34, wherein said composition comprises an undetectable amount of cytokines, growth factors or deoxycholic acid.~~

~~36. The composition of claim 35, wherein said composition comprises less than about 0.1% fibronectin, less than about 0.1% laminin, less than about 0.1% glycosaminoglycans, and an undetectable amount of cytokines, growth factors or deoxycholic acid.~~

~~37. The composition of claim 36, wherein said composition comprises less than about 0.1% fibronectin, less than about 0.1% laminin, less than about 0.1% glycosaminoglycans, and an undetectable amount of cytokines, growth factors and deoxycholic acid.~~

~~38. The composition of any one of claims 19-37, wherein said ECM is placental ECM.~~

~~39.~~20. The ~~composition~~method of ~~claim 38~~ any one of claims 17-19, wherein said ~~placental ECM~~placenta is human placenta~~l ECM~~.

~~40.~~21. The ~~composition~~method of any one of claims ~~19-39~~17-20, wherein said composition is formulated as a sheet.

~~41.~~22. The ~~composition~~method of claim ~~40~~21, wherein said sheet is ~~about~~ 1.5 to 2.5 mm thick.

~~42.~~23. The ~~composition~~method of any one of claims ~~19-39~~17-20, wherein said composition is formulated as a particulate.

~~43.~~24. The ~~composition~~method of any one of claims ~~19-39~~17-20, wherein said composition is formulated as a flowable matrix.

~~44.~~25. The use of the extracellular matrix of any one of claims 1-16 in the manufacture of a medicament for the treatment ~~A method of treating~~ of a subject in need of extracellular matrix (ECM), ~~comprising administering to the subject, or contacting the subject with the composition of any one of claims 1-43.~~

~~45. The method of claim 44,~~ wherein said subject has an oral lesion~~.~~

~~46. The method of claim 44~~, wherein said subject has urinary incontinence~~.~~

~~47. The method of claim 44~~, wherein said subject has vesicoureteral reflux~~.~~

~~48. The method of claim 44~~, wherein said subject has gastroesophageal reflux disease~~.~~

~~49. The method of claim 44, wherein said subject has~~ a disease, disorder, or abnormality that affects one or both vocal cords and/or the larynx~~.~~

~~50. The method of claim 44, wherein said subject has~~ or glottic incompetence.

~~51.~~26. The ~~method~~use of claim ~~44~~25, wherein said ECM is used as a nerve guide.

~~52.~~27. The ~~method~~use of claim ~~44~~25, wherein said ECM is used as a tendon wrap.

~~53.~~28. The ~~method~~use of claim ~~44~~25, wherein said ECM is used as a dural replacement.

~~54.~~29. A non-surgical method of treating cosmetic defect in a subject, ~~The method of claim 44, wherein said subject has a cosmetic defect~~ the method comprising administering to a subject, or contacting a subject with the composition of any one of claims 1 to 16.

~~55.~~30. The method of claim ~~54~~29, wherein said cosmetic defect is wrinkles, depressions, creases, stretch marks, scars, hollow eyes, or visible vessels resulting in dark circles around the eyes.